Hinshaw's Chargo Weighs Cannabis M&A After Rescheduling

What Hinshaw published and why dealmakers are watching

Hinshaw & Culbertson LLP put out a discussion with partner Mitch Chargo on cannabis M&A in a post-rescheduling landscape, according to a Nov. 12, 2026 Google News listing.

What CannIntel has in hand is the headline and the publisher attribution. There's no transcript, so this report doesn't attribute specific statements to Chargo beyond the topic of the discussion.

That limit matters. What follows is analysis of the issues any post-rescheduling cannabis deal has to price, not a recap of what Chargo said.

The 280E question sits at the center of every model

The biggest swing factor in cannabis deal math is whether a Schedule III classification ends the Section 280E tax penalty for plant-touching operators.

Under 280E, businesses trafficking in Schedule I or II substances can't deduct ordinary operating expenses. Effective tax rates for many MSOs have run well above statutory levels as a result. A Schedule III designation would remove cannabis from 280E's reach, according to the statute's text.

For an acquirer, that rewires the model. Pre-tax EBITDA multiples have long understated the cash-tax drag on target companies, and once the drag is gone, the same asset throws off more free cash flow per dollar of EBITDA.

Sellers know it. Expect them to argue for pricing off a normalized tax rate, while buyers push back that they shouldn't pay for a benefit they haven't yet received.

Who pays for the tax benefit: the buyer or the seller

Deal teams are likely to fight over who captures the 280E upside, and the fight shows up in price, earnouts and contingent consideration.

Buyers have several tools to hedge timing risk. Earnouts tied to realized cash taxes, price adjustments keyed to the effective date of any rule, and escrows against retroactive disputes all shift risk back toward the seller.

Look closely at how filings describe these provisions. Contingent value rights and tax-benefit sharing clauses will tell you which side held leverage.

One fact favors buyers. Operators with thin balance sheets and heavy debt loads can't wait for a regulatory fix. Lenders know it.

Diligence scope expands, not shrinks

Rescheduling does not make cannabis targets look like ordinary commerce, and acquirers will still need to diligence state licensing, banking and federal exposure.

Schedule III is a federal classification change. State licensing regimes, including California's Department of Cannabis Control and New York's Office of Cannabis Management, still govern who can own and operate a license. Change-of-control approvals, ownership caps and residency rules don't disappear.

Federal exposure changes in character rather than vanishing. Schedule III substances remain controlled. Counsel will still ask whether adult-use sales fit within the prescription-based framework that governs other Schedule III drugs, and the scheduling label alone doesn't settle that question.

Public acquirers face disclosure obligations too. Risk-factor language in 10-Ks and merger proxies will need updating, and securities counsel will want each representation checked against what the target actually does.

Capital markets and the uplisting trade

Rescheduling revives the argument that large MSOs could move toward major U.S. exchanges, which would change both currency and cost of capital for stock-funded deals.

Most large U.S. multistate operators trade over the counter or on Canadian venues, with thin liquidity and valuation discounts. A cleaner federal status is the precondition for any serious uplisting conversation. It's no guarantee.

Stock as acquisition currency only works if the paper holds value. A premium multiple on an uplisted MSO would let it buy regional operators with equity instead of expensive debt. Without that premium, cash and seller notes keep dominating deal structure.

What operators should do before the next term sheet

Operators weighing a sale or a purchase should model three scenarios: no 280E relief, partial relief, and full relief with a defined effective date.

Run each case on after-tax free cash flow, not headline EBITDA. Then test how the purchase price, debt covenants and earnout triggers behave under each one.

Companies with large accrued 280E liabilities face a separate issue. Whether relief applies prospectively only or reaches open tax years will drive reserve decisions and negotiating posture on both sides.

For the regulatory backdrop and how the rescheduling process got here, see the CannIntel topic hub on DEA rescheduling.

The next signal to watch

The first closed deals priced explicitly off a post-280E tax rate will set the market's reference multiple.

Watch 8-K filings and merger proxies for tax-benefit sharing language, contingent consideration tied to 280E, and any revised effective-tax-rate guidance from the large operators. Those disclosures will show where buyers and sellers actually landed. That counts for more than any law-firm commentary.